In the reported data in Western populations (cBioPortal and MDACC), ERBB2 mutations were most commonly observed in the tyrosine kinase domain (46%), with mutations in exon 20 (20%), exon 19 (11%), and exon 21 (9%) across all cancers [28]. This evidence concerns the gene ERBB2 and cancer.